BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10606321)

  • 1. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy.
    Herrera JL
    Am J Gastroenterol; 1999 Dec; 94(12):3571-5. PubMed ID: 10606321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy.
    Tsai NC; Zuckerman E; Han SH; Goad K; Redeker AG; Fong TL
    Am J Gastroenterol; 1997 Oct; 92(10):1831-4. PubMed ID: 9382046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study].
    Ortiz V; Olaso V; López Viedma B; Córdoba J; Molina JM; Lainez B; Pastor M; Berenguer J
    Gastroenterol Hepatol; 1999 Mar; 22(3):122-6. PubMed ID: 10228321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.
    Fong TL; Han SH; Tsai NC; Morgan TR; Mizokami M; Qian D; Phan C; Goad K; Redeker AG
    J Hepatol; 1998 Mar; 28(3):369-74. PubMed ID: 9551672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study.
    Fargion S; Fracanzani AL; Rossini A; Borzio M; Riggio O; Belloni G; Bissoli F; Ceriani R; Ballarè M; Massari M; Trischitta C; Fiore P; Orlandi A; Morini L; Mattioli M; Oldani S; Cesana B; Fiorelli G
    Am J Gastroenterol; 2002 May; 97(5):1204-10. PubMed ID: 12014729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
    Blatt LM; Tong MJ; McHutchison JG; Russell J; Schmid P; Conrad A
    J Interferon Cytokine Res; 1998 Feb; 18(2):75-80. PubMed ID: 9506457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial.
    Di Bisceglie AM; Bonkovsky HL; Chopra S; Flamm S; Reddy RK; Grace N; Killenberg P; Hunt C; Tamburro C; Tavill AS; Ferguson R; Krawitt E; Banner B; Bacon BR
    Hepatology; 2000 Jul; 32(1):135-8. PubMed ID: 10869301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study.
    Alexander J; Tung BY; Croghan A; Kowdley KV
    Liver Int; 2007 Mar; 27(2):268-73. PubMed ID: 17311623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection.
    Kawamura Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2005 Sep; 40(9):901-6. PubMed ID: 16211347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2B.
    Sim H; Yim C; Krajden M; Heathcote J
    Am J Gastroenterol; 1998 Jan; 93(1):39-43. PubMed ID: 9448171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.
    Vogel W; Graziadei I; Umlauft F; Datz C; Hackl F; Allinger S; Grünewald K; Patsch J
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):81S-85S. PubMed ID: 9011481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial.
    Fontana RJ; Israel J; LeClair P; Banner BF; Tortorelli K; Grace N; Levine RA; Fiarman G; Thiim M; Tavill AS; Bonkovsky HL
    Hepatology; 2000 Mar; 31(3):730-6. PubMed ID: 10706565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated serum ALT levels during pegylated interferon monotherapy may be caused by hepatic iron overload.
    Nagashima M; Kudo M; Chung H; Ishikawa E; Inoue T; Nakatani T; Dote K
    Intervirology; 2008; 51 Suppl 1():76-85. PubMed ID: 18544952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C.
    Fargion S; Fracanzani AL; Sampietro M; Molteni V; Boldorini R; Mattioli M; Cesana B; Lunghi G; Piperno A; Valsecchi C; Fiorelli G
    Eur J Gastroenterol Hepatol; 1997 May; 9(5):497-503. PubMed ID: 9187884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of blood letting on serum aminotransferase levels of patients with chronic hepatitis C and iron overload.
    Girelli CM; Mirata C; Casiraghi A
    Recenti Prog Med; 1998 May; 89(5):241-4. PubMed ID: 9676130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group.
    Jensen DM; Krawitt EL; Keeffe EB; Hollinger FB; James SP; Mullen K; Everson GT; Hoefs JC; Fromm H; Black M; Foust RT; Pimstone NR; Heathcote EJ; Albert D
    Am J Gastroenterol; 1999 Dec; 94(12):3583-8. PubMed ID: 10606323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily interferon therapy for chronic hepatitis C: a report of a community practice experience.
    Srinivas D; Mani H; Crumpler C; Van Thiel DH
    Hepatogastroenterology; 2002; 49(46):1053-7. PubMed ID: 12143200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.